Products for Research Use Only

Omaveloxolone

CAT: 0804-HY-12212-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-12212-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Omaveloxolone (RTA 408) is an antioxidant inflammation modulator (AIM), which activates Nrf2 and suppresses nitric oxide (NO) . Omaveloxolone attenuates osteoclastogenesis by inhibiting STING dependent NF-κb signaling.
CAS Number
1474034-05-3
Product Name Alternative
RTA 408
UNSPSC
12352211
Target
Apoptosis; Keap1-Nrf2; STING
Type
Reference compound
Related Pathways
Apoptosis; Immunology/Inflammation; NF-κB
Applications
Cancer-programmed cell death
Field of Research
Cancer; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/RTA-408.html
Purity
99.52
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C1C(C#N)=C[C@@]2(C)[C@](CC[C@]([C@@]3(C)[C@@]4([H])[C@@]5([H])[C@@](CCC(C)(C)C5)(NC(C(F)(F)C)=O)CC3)(C)C2=CC4=O)([H])C1(C)C
Molecular Formula
C33H44F2N2O3
Molecular Weight
554.71
References & Citations
[1]Probst BL, et al. RTA 408, A Novel Synthetic Triterpenoid with Broad Anticancer and Anti-Inflammatory Activity. PLoS One. 2015 Apr 21;10 (4) :e0122942.|[2]Goldman DC, et al. The triterpenoid RTA 408 is a robust mitigator of hematopoietic acute radiation syndrome in mice. Radiat Res. 2015 Mar;183 (3) :338-44|[3]Peng Han, et al. RTA-408 Protects Kidney from Ischemia-Reperfusion Injury in Mice via Activating Nrf2 and Downstream GSH Biosynthesis Gene. Oxid Med Cell Longev. 24 December 2017.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched